TD Cowen Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences (NASDAQ:GILD) had its target price raised by stock analysts at TD Cowen from $125.00 to $145.00 in a research note issued on Thursday,MarketScreener reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. TD Cowen’s price target would indicate a potential upside of 3.91% from the stock’s current price.

A number of other research analysts have also recently issued reports on the stock. Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a report on Thursday, January 22nd. The Goldman Sachs Group increased their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the company a “neutral” rating in a research note on Thursday, January 8th. Wolfe Research increased their price objective on shares of Gilead Sciences from $150.00 to $155.00 and gave the company an “outperform” rating in a research report on Wednesday. Wells Fargo & Company upped their price objective on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. Finally, Truist Financial increased their target price on Gilead Sciences from $140.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $136.36.

Gilead Sciences Trading Down 0.1%

Shares of Gilead Sciences stock opened at $139.55 on Thursday. Gilead Sciences has a 12-month low of $93.37 and a 12-month high of $141.71. The company has a 50-day simple moving average of $125.05 and a 200 day simple moving average of $119.38. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The stock has a market capitalization of $173.14 billion, a P/E ratio of 21.64, a price-to-earnings-growth ratio of 0.73 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company’s revenue was up 3.0% on a year-over-year basis. During the same period in the previous year, the firm posted $2.02 earnings per share. Research analysts expect that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Insider Buying and Selling at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction on Friday, November 28th. The stock was sold at an average price of $125.08, for a total value of $625,400.00. Following the sale, the director owned 8,920 shares in the company, valued at approximately $1,115,713.60. The trade was a 35.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $124.31, for a total value of $372,930.00. Following the transaction, the chief financial officer directly owned 150,503 shares of the company’s stock, valued at approximately $18,709,027.93. This represents a 1.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 257,397 shares of company stock worth $33,385,512. 0.27% of the stock is currently owned by corporate insiders.

Institutional Trading of Gilead Sciences

A number of large investors have recently made changes to their positions in GILD. GoalVest Advisory LLC raised its stake in shares of Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the last quarter. Corundum Trust Company INC purchased a new position in shares of Gilead Sciences in the 3rd quarter valued at $26,000. Harbor Asset Planning Inc. purchased a new position in Gilead Sciences in the 2nd quarter worth approximately $27,000. Ares Financial Consulting LLC purchased a new stake in shares of Gilead Sciences during the fourth quarter worth about $28,000. Finally, Financial Consulate Inc. boosted its stake in shares of Gilead Sciences by 85.8% during the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 109 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Trodelvy received a boost after being added to NCCN treatment guidelines, improving adoption and commercial prospects for Gilead’s oncology franchise. Trodelvy NCCN
• Positive Sentiment: Clinical/market coverage highlighted Trodelvy’s win in triple-negative breast cancer (TNBC), underscoring upside to oncology revenue growth and pipeline credibility. Trodelvy TNBC
• Positive Sentiment: Wolfe Research raised its price target to $155 and maintained an “outperform” rating, signaling analyst conviction and potential buy-side interest. Wolfe PT Raise
• Positive Sentiment: Multiple broker notes (Citigroup, Truist and others) reiterated bullish forecasts and higher targets, which can support demand and price appreciation if momentum continues. Citigroup Forecast Truist Forecast
• Neutral Sentiment: Zacks and other coverage note increased investor attention and search activity on GILD — this can raise volume but is not a direct directional catalyst. Zacks Note
• Neutral Sentiment: Reported short-interest figures appear inconsistent (data glitch flagged); there’s no clear evidence of elevated shorting or an imminent short-squeeze from the available data.
• Negative Sentiment: Insider selling: CEO Daniel O’Day sold 10,000 shares (~$1.4M) at about $139.89 (one of several recent sales). Such insider disposals can be interpreted as negative by some investors, prompting short-term selling or caution. SEC Form 4

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.